Cat. No.: HY-107455

A-485

110 Cited Publications

Avis client

Based on 110 publication(s) in Google Scholar

A-485, a chemical probe, is a potent and selective catalytic inhibitor of p300/CBP with IC₅₀s of 9.8 nM and 2.6 nM for p300 and CBP histone acetyltransferase (HAT), respectively.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.87%
CAS No.: 1889279-16-6
Formule: C₂₅H₂₄F₄N₄O₅
Masse moléculaire:536.48

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

A-485 Chemical Structure

CAS No.: 1889279-16-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (110)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

A-485, a chemical probe, is a potent and selective catalytic inhibitor of p300/CBP with IC₅₀s of 9.8 nM and 2.6 nM for p300 and CBP histone acetyltransferase (HAT), respectively^[1].

IC₅₀ & Target

CBP/p300

Voir tous les produits spécifiques à Isoform Epigenetic Reader Domain :

Voir tous les produits spécifiques à Isoform Histone Acetyltransferase :

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
A-375	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
AMO1	EC₅₀	1.09 μM Compound: A-485	Antiproliferative activity against human AMO1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human AMO1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
BJAB	EC₅₀	0.28 μM Compound: A-485	Antiproliferative activity against human BJAB cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human BJAB cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
BT-20	EC₅₀	0.34 μM Compound: A-485	Antiproliferative activity against human BT-20 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human BT-20 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
CA46	EC₅₀	0.48 μM Compound: A-485	Antiproliferative activity against human CA46 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human CA46 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
CAL-120	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human CAL-120 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human CAL-120 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Calu-6	EC₅₀	8.57 μM Compound: A-485	Antiproliferative activity against human Calu-6 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Calu-6 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
CHL-1	EC₅₀	0.37 μM Compound: A-485	Antiproliferative activity against human CHL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human CHL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
COLO-679	EC₅₀	2.26 μM Compound: A-485	Antiproliferative activity against human COLO-679 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human COLO-679 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
COR-L47	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human COR-L47 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human COR-L47 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
CWR22R	EC₅₀	0.32 μM Compound: A-485	Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
CWR22R	IC₅₀	490 nM Compound: A-485	Antiproliferative activity against human 22Rv1 cells measured after 3 days by celltiter-glo luminescence assay Antiproliferative activity against human 22Rv1 cells measured after 3 days by celltiter-glo luminescence assay	[PMID: 31910017]
Daudi	EC₅₀	0.43 μM Compound: A-485	Antiproliferative activity against human Daudi cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Daudi cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
DB	EC₅₀	0.77 μM Compound: A-485	Antiproliferative activity against human DB cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human DB cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
DOHH-2	EC₅₀	0.75 μM Compound: A-485	Antiproliferative activity against human DOHH-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human DOHH-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
DU-145	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human DU-145 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
DU-4475	EC₅₀	0.67 μM Compound: A-485	Antiproliferative activity against human DU-4475 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human DU-4475 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
EMT6	EC₅₀	0.5 μM Compound: A-485	Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
EOL1	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human EOL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human EOL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Farage	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human Farage cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Farage cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
G-361	EC₅₀	3.77 μM Compound: A-485	Antiproliferative activity against human G361 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human G361 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
GA-10	EC₅₀	1.06 μM Compound: A-485	Antiproliferative activity against human GA-10 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human GA-10 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Granta-519	EC₅₀	3.28 μM Compound: A-485	Antiproliferative activity against human Granta-519 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Granta-519 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HCC1143	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human HCC1143 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HCC1143 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HCC1187	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human HCC1187 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HCC1187 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HCC1395	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human HCC1395 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HCC1395 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HCC1599	EC₅₀	4.85 μM Compound: A-485	Antiproliferative activity against human HCC1599 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HCC1599 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HCC1806	EC₅₀	2.95 μM Compound: A-485	Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HCC1937	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human HCC1937 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HCC1937 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HCC2935	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human HCC2935 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HCC2935 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HCC38	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human HCC38 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HCC38 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HCC4006	EC₅₀	4.64 μM Compound: A-485	Antiproliferative activity against human HCC4006 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HCC4006 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HCC70	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human HCC70 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HCC70 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HEL	EC₅₀	3.09 μM Compound: A-485	Antiproliferative activity against human HEL cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HEL cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HL-60	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Hs 294T	EC₅₀	9 μM Compound: A-485	Antiproliferative activity against human Hs294T cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Hs294T cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Hs 695T	EC₅₀	3.57 μM Compound: A-485	Antiproliferative activity against human Hs 695T cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Hs 695T cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HT	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human HT cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HT cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
HT-144	EC₅₀	3.08 μM Compound: A-485	Antiproliferative activity against human HT-144 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human HT-144 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Jurkat	EC₅₀	4.03 μM Compound: A-485	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
JVM-2	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human JVM-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human JVM-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
K562	EC₅₀	1.27 μM Compound: A-485	Antiproliferative activity against human K562 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human K562 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
K562	IC₅₀	457 nM Compound: A-485	Antiproliferative activity against human K562 cells measured after 3 days by celltiter-glo luminescence assay Antiproliferative activity against human K562 cells measured after 3 days by celltiter-glo luminescence assay	[PMID: 31910017]
Karpas-1106P	EC₅₀	0.41 μM Compound: A-485	Antiproliferative activity against human KARPAS-1106P cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human KARPAS-1106P cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
KARPAS-299	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
KARPAS-422	EC₅₀	0.25 μM Compound: A-485	Antiproliferative activity against human KARPAS-422 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human KARPAS-422 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Kasumi 1	EC₅₀	0.29 μM Compound: A-485	Antiproliferative activity against human Kasumi 1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Kasumi 1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Kasumi 1	EC₅₀	0.33 μM Compound: A-485	Antiproliferative activity against human Kasumi-1 cells assessed as reduction in cell viability incubated for 5 days by XTT assay Antiproliferative activity against human Kasumi-1 cells assessed as reduction in cell viability incubated for 5 days by XTT assay	[PMID: 32314924]
Kasumi 1	IC₅₀	607.9 nM Compound: A-485	Antiproliferative activity against human Kasumi-1 cells measured after 3 days by celltiter-glo luminescence assay Antiproliferative activity against human Kasumi-1 cells measured after 3 days by celltiter-glo luminescence assay	[PMID: 31910017]
KMS-11	EC₅₀	0.24 μM Compound: A-485	Antiproliferative activity against human KMS-11 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human KMS-11 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
L-363	EC₅₀	0.51 μM Compound: A-485	Antiproliferative activity against human L-363 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human L-363 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
LNCaP	EC₅₀	0.26 μM Compound: A-485	Antiproliferative activity against human LNCaP cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human LNCaP cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay	[PMID: 35512565]
LNCaP	EC₅₀	446 nM Compound: 1; A-485	Antiproliferative activity against human LNCAP cells Antiproliferative activity against human LNCAP cells	[PMID: 33631370]
LNCaP	IC₅₀	1.7 μM Compound: A485	Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38215590]
LNCaP-Clone-FGC	EC₅₀	0.26 μM Compound: A-485	Antiproliferative activity against human LNCaP-Clone-FGC cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human LNCaP-Clone-FGC cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
LNCaP-Clone-FGC	EC₅₀	0.35 μM Compound: 1; A-485	Antiproliferative activity against AR-positive human LNCaP-Clone-FGC cells assessed as inhibition of cell proliferation measured after 5 days by luminiscent plate reader method Antiproliferative activity against AR-positive human LNCaP-Clone-FGC cells assessed as inhibition of cell proliferation measured after 5 days by luminiscent plate reader method	[PMID: 34055218]
LNCaP-Clone-FGC	IC₅₀	215 nM Compound: A-485	Antiproliferative activity against human LNCaP-FGC cells measured after 5 days by celltiter-glo luminescence assay Antiproliferative activity against human LNCaP-FGC cells measured after 5 days by celltiter-glo luminescence assay	[PMID: 31910017]
Malme-3M	EC₅₀	2.69 μM Compound: A-485	Antiproliferative activity against human Malme-3M cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Malme-3M cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Maver1	IC₅₀	226.1 nM Compound: A-485	Antiproliferative activity against human Maver1 cells measured after 3 days by celltiter-glo luminescence assay Antiproliferative activity against human Maver1 cells measured after 3 days by celltiter-glo luminescence assay	[PMID: 31910017]
MCF7	EC₅₀	>30 μM Compound: A-485	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 6 days by Celigo-insitu cell cytometer analysis Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 6 days by Celigo-insitu cell cytometer analysis	[PMID: 32314924]
MCF7	EC₅₀	>30 μM Compound: A-485	Antiproliferative activity against human tamoxifen-resistant MCF7 cells assessed as reduction in cell viability incubated for 6 days by Celigo-insitu cell cytometer analysis Antiproliferative activity against human tamoxifen-resistant MCF7 cells assessed as reduction in cell viability incubated for 6 days by Celigo-insitu cell cytometer analysis	[PMID: 32314924]
MCF7	IC₅₀	>30 μM Compound: A485	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38215590]
MDA-MB-157	EC₅₀	4.59 μM Compound: A-485	Antiproliferative activity against human MDA-MB-157 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human MDA-MB-157 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
MDA-MB-231	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay	[PMID: 35512565]
MDA-MB-231	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
MDA-MB-436	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
MDA-MB-453	EC₅₀	1.87 μM Compound: A-485	Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
MDA-MB-468	EC₅₀	0.38 μM Compound: A-485	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
MeWo	EC₅₀	2.43 μM Compound: A-485	Antiproliferative activity against human MeWo cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human MeWo cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
MM1.S	EC₅₀	0.18 μM Compound: A-485	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human MM1.S cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
MM1.S	EC₅₀	139 nM Compound: A-485	Antiproliferative activity against human MM1.S cells assessed as reduction in cell proliferation incubated for 72 hrs by MTS assay Antiproliferative activity against human MM1.S cells assessed as reduction in cell proliferation incubated for 72 hrs by MTS assay	[PMID: 35814928]
MOLM-13	EC₅₀	0.35 μM Compound: A-485	Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay	[PMID: 35512565]
MOLM-13	EC₅₀	0.35 μM Compound: A-485	Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
MOLT-4	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
MV4-11	IC₅₀	255.2 nM Compound: A-485	Antiproliferative activity against human MV4-11 cells measured after 3 days by celltiter-glo luminescence assay Antiproliferative activity against human MV4-11 cells measured after 3 days by celltiter-glo luminescence assay	[PMID: 31910017]
NCI-H1048	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human NCI-H1048 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H1048 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H128	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human NCI-H128 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H128 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H1373	EC₅₀	2.34 μM Compound: A-485	Antiproliferative activity against human NCI-H1373 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H1373 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H1417	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human NCI-H1417 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H1417 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H146	EC₅₀	0.4 μM Compound: A-485	Antiproliferative activity against human NCI-H146 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H146 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H1693	EC₅₀	2.37 μM Compound: A-485	Antiproliferative activity against human NCI-H1693 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H1693 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H1836	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human NCI-H1836 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H1836 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H187	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human NCI-H187 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H187 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H1930	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human NCI-H1930 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H1930 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H2081	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human NCI-H2081 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H2081 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H209	EC₅₀	0.4 μM Compound: A-485	Antiproliferative activity against human NCI-H209 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H209 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H211	EC₅₀	1.5 μM Compound: A-485	Antiproliferative activity against human NCI-H211 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H211 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H23	EC₅₀	1.79 μM Compound: A-485	Antiproliferative activity against human NCI-H23 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H23 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H2444	EC₅₀	5.92 μM Compound: A-485	Antiproliferative activity against human NCI-H2444 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H2444 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H441	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human NCI-H441 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H441 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H510A	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human NCI-H510A cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H510A cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H522	EC₅₀	3.52 μM Compound: A-485	Antiproliferative activity against human NCI-H522 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H522 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H596	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human NCI-H596 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H596 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H661	EC₅₀	7.66 μM Compound: A-485	Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H69	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human NCI-H69 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H69 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H727	EC₅₀	6.63 μM Compound: A-485	Antiproliferative activity against human NCI-H727 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H727 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H838	EC₅₀	6.99 μM Compound: A-485	Antiproliferative activity against human NCI-H838 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H838 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NCI-H929	EC₅₀	0.33 μM Compound: A-485	Antiproliferative activity against human NCI-H929 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H929 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NU-DHL-1	EC₅₀	0.53 μM Compound: A-485	Antiproliferative activity against human NU-DHL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NU-DHL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
NU-DUL-1	EC₅₀	0.48 μM Compound: A-485	Antiproliferative activity against human NU-DUL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human NU-DUL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
OCI-AML2	EC₅₀	2.03 μM Compound: A-485	Antiproliferative activity against human OCI-AML2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human OCI-AML2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
OCI-AML-5	EC₅₀	4.86 μM Compound: A-485	Antiproliferative activity against human OCI-AML5 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human OCI-AML5 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
OCI-Ly1	EC₅₀	0.94 μM Compound: A-485	Antiproliferative activity against human OCI-Ly1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human OCI-Ly1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
OCI-Ly18	EC₅₀	0.32 μM Compound: A-485	Antiproliferative activity against human OCI-Ly18 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human OCI-Ly18 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
OCI-Ly3	EC₅₀	0.49 μM Compound: A-485	Antiproliferative activity against human OCILY3 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human OCILY3 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
OCI-Ly7	EC₅₀	1.81 μM Compound: A-485	Antiproliferative activity against human OCILY7 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human OCILY7 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
OPM-2	EC₅₀	0.62 μM Compound: A-485	Antiproliferative activity against human OPM-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human OPM-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
OVCAR-3	EC₅₀	5.44 μM Compound: A-485	Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 120 hrs by Cell-titre glo assay Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 120 hrs by Cell-titre glo assay	[PMID: 34801827]
PANC-1	EC₅₀	>30 μM Compound: A-485	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32314924]
PANC-1	IC₅₀	>30 μM Compound: A485	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38215590]
PC-3	EC₅₀	2.05 μM Compound: A-485	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
PC-3	EC₅₀	2.1 μM Compound: A-485	Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay	[PMID: 35512565]
Pfeiffer	EC₅₀	0.86 μM Compound: A-485	Antiproliferative activity against human Pfeiffer cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Pfeiffer cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Raji	EC₅₀	0.46 μM Compound: A-485	Antiproliferative activity against human Raji cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Raji cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Ramos	EC₅₀	0.93 μM Compound: A-485	Antiproliferative activity against human Ramos cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Ramos cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
RCK8	EC₅₀	0.59 μM Compound: A-485	Antiproliferative activity against human RCK8 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human RCK8 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Rec1	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human REC1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human REC1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
RL	EC₅₀	1.05 μM Compound: A-485	Antiproliferative activity against human RL cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human RL cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
RPMI-8226	EC₅₀	0.16 μM Compound: A-485	Antiproliferative activity against human RPMI-8226 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human RPMI-8226 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay	[PMID: 35512565]
RPMI-8226	EC₅₀	0.16 μM Compound: A-485	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
SET-2	EC₅₀	2.01 μM Compound: A-485	Antiproliferative activity against human SET2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human SET2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Sf9	IC₅₀	0.06 μM Compound: A-485	Inhibition of recombinant human N-terminal 6His-FLAG-tagged p300 BHC domain (1036 to 1822 residues) expressed in baculovirus infected Sf9 insect cells using biotinylated-histone H4 peptide as substrate preincubated for 30 mins followed by substrate additi Inhibition of recombinant human N-terminal 6His-FLAG-tagged p300 BHC domain (1036 to 1822 residues) expressed in baculovirus infected Sf9 insect cells using biotinylated-histone H4 peptide as substrate preincubated for 30 mins followed by substrate additi	[PMID: 31910017]
SKM-1	EC₅₀	1.34 μM Compound: A-485	Antiproliferative activity against human SKM-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human SKM-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
SK-MEL-1	EC₅₀	0.57 μM Compound: A-485	Antiproliferative activity against human SK-MEL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human SK-MEL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
SK-MEL-2	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human SK-MEL-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human SK-MEL-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
SK-MEL-24	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human SK-MEL-24 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human SK-MEL-24 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
SK-MEL-5	EC₅₀	0.91 μM Compound: A-485	Antiproliferative activity against human SK-MEL-5 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human SK-MEL-5 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
SUD4	EC₅₀	0.72 μM Compound: A-485	Antiproliferative activity against human SU-DHL-4 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human SU-DHL-4 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
SU-DHL10	EC₅₀	0.92 μM Compound: A-485	Antiproliferative activity against human Su-DHL-10 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Su-DHL-10 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
SU-DHL-16	EC₅₀	0.73 μM Compound: A-485	Antiproliferative activity against human SU-DHL-16 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human SU-DHL-16 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
SU-DHL-2	EC₅₀	0.95 μM Compound: A-485	Antiproliferative activity against human SUDHL2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human SUDHL2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
SU-DHL-5	EC₅₀	0.76 μM Compound: A-485	Antiproliferative activity against human SuDHL5 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human SuDHL5 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
SU-DHL-6	EC₅₀	0.75 μM Compound: A-485	Antiproliferative activity against human SU-DHL-6 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human SU-DHL-6 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
SU-DHL-8	EC₅₀	0.54 μM Compound: A-485	Antiproliferative activity against human SU-DHL-8 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human SU-DHL-8 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
THP-1	EC₅₀	3.51 μM Compound: A-485	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
Toledo	EC₅₀	0.49 μM Compound: A-485	Antiproliferative activity against human Toledo cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human Toledo cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
U2932	EC₅₀	2.46 μM Compound: A-485	Antiproliferative activity against human U2932 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human U2932 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
U-2940	EC₅₀	1.33 μM Compound: A-485	Antiproliferative activity against human U-2940 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human U-2940 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
U-2973	EC₅₀	0.66 μM Compound: A-485	Antiproliferative activity against human U-2973 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human U-2973 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
U-937	EC₅₀	>10 μM Compound: A-485	Antiproliferative activity against human U937 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human U937 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
ULA	EC₅₀	0.55 μM Compound: A-485	Antiproliferative activity against human ULA cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human ULA cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
VCaP	EC₅₀	0.04 μM Compound: A-485	Antiproliferative activity against human VCaP cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human VCaP cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
WM 266-4	EC₅₀	1.91 μM Compound: A-485	Antiproliferative activity against human WM266-4 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human WM266-4 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]
WSU-NHL	EC₅₀	1.06 μM Compound: A-485	Antiproliferative activity against human WSU-NHL cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay Antiproliferative activity against human WSU-NHL cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay	[PMID: 28953875]

In Vitro

A three-hour treatment of prostate adenocarcinoma PC-3 cells with A-485 results in a dose-dependent decrease in H3K27Ac, with a half maximal effective concentration (EC₅₀) of 73 nM. Treatment with A-485 does not alter p300 or CBP protein levels.
The broadest sensitivity is observed in haematological tumours, where A-485 exhibits potent activity in most multiple myeloma cell lines, and in a subset of acute myeloid leukaemia lines and non-Hodgkin’s lymphoma lines. A-485 induces a comparable decrease in H3K27Ac in all five prostate cancer cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

After tumours are established in SCID male mice, twice daily intraperitoneal injections of A-485 induce 54% tumour growth inhibition after 21 days of dosing (P<0.005 as compare to vehicle control). In addition, in tumour-bearing animals, dosing with A-485 for seven days induces a decrease in the mRNA levels of MYC and the AR-dependent gene SLC45A3 at three hours post-dosing, and (for MYC) a decrease in the protein level, indicating that A-485 inhibits p300-mediated transcriptional activity in vivo. However, at 16 hours post-dosing on the seventh day, A-485 drug levels in the plasma and tumour are decreased as compare to 3 hours. A-485 induces a moderate 9% body weight loss, and the animals recover rapidly upon completion of the A-485 dosing regimen^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1889279-16-6
Appearance Solid
Masse moléculaire 536.48
Formule C₂₅H₂₄F₄N₄O₅
Color White to off-white
SMILES

O=C(N1CC(N([C@@H](C)C(F)(F)F)CC2=CC=C(F)C=C2)=O)[C@]3(OC1=O)C4=CC=C(NC(NC)=O)C=C4CC3
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (110)

All WBCell Proliferation/Viability AssayIFIHCCell Migration/Invasion AssayRT-PCR

Sort by:

Journal Impact Factor

Cancer Cell

Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. [Abstract]

2026 Mar 19:S1535-6108(26)00111-X. PMID: 41875889
Nature

Acetyl-methyllysine marks chromatin at active transcription start sites. [Abstract]

2023 Oct;622(7981):173-179. PMID: 37731000

A-485 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Oct;622(7981):173-179. [Abstract]

Representative western blots of two biological replicates of HEK293T histones treated with A-485 and NU9056 (10 μM for 24 hours)

A-485 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Oct;622(7981):173-179. [Abstract]

Kacme (top) and H3K27ac (bottom) ChIP-qPCR in HEK293T cells after A-485 treatment (10 μM for 24 hours).

A-485 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Oct;622(7981):173-179. [Abstract]

qPCR results showing relative expression levels of indicated transcripts in HEK293T cells after A-485 treatment (10 μM for 24 hours).

A-485 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Oct;622(7981):173-179. [Abstract]

Quantifications of Transwell assays in indicated PANC-1 cells treated with different concentrations of A-485 (1.25-5 μM)
Cancer Cell

The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability. [Abstract]

2019 Dec 9;36(6):630-644.e9. PMID: 31735627

A-485 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2019 Dec 9;36(6):630-644.e9. [Abstract]

Western blot of MYC in PDX (11a) cells after ex vivo treatment with A-485 (0.1-1 μM) for 6 h.
Cell

p53 safeguards chemical reprogramming of human somatic cells toward pluripotency. [Abstract]

2026 Jun 11;189(12):3541-3552.e18. PMID: 41999746
Cell

Composite transposons with bivalent histone marks function as RNA-dependent enhancers in cell fate regulation. [Abstract]

2025 Oct 16;188(21):5878-5894.e18. PMID: 40774253
Cell

Long-term histone lactylation connects metabolic and epigenetic rewiring in innate immune memory. [Abstract]

2025 May 29;188(11):2992-3012.e16. PMID: 40318634

A-485 purchased from MedChemExpress. Usage Cited in: Cell. 2025 May 29;188(11):2992-3012.e16. [Abstract]

Human monocytes were stimulated with BCG, LPS (1 ng/mL or indicated concentrations), or cultured in medium (RPMI) ± the indicated concentrations of A-485 (p300i, 1 μM) for 24 h. An MTT assay is used to assess the cellular viability (n = 6 donors, mean ± SEM).
Nat Biotechnol

CRISPR live-cell imaging reveals chromatin dynamics and enhancer interactions at multiple non-repetitive loci. [Abstract]

2025 Nov 6. PMID: 41199023
Immunity

Small-molecule CBP/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response. [Abstract]

2024 Feb 13;57(2):364-378.e9. PMID: 38301651
Nat Immunol

Ammonia detoxification promotes CD8+ T cell memory development by urea and citrulline cycles. [Abstract]

2023 Jan;24(1):162-173. PMID: 36471170

A-485 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]

A485 (10 μM; 24 h) leads to the downregulation of H3K9bhb and CPS1 in BHB-treated CD8⁺ T_M cells; however, the use of 3-TYP (10 μM; 24 h) or Trichostatin A (TSA; 5 nM; 24 h) result in the increase of H3K9bhb and CPS1.

A-485 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]

T_M cells (IL-15-derived) were treated with 3TY (10 μM), TSA (5 nM), A-485 (10 μM) or BHB (5 mM) for 24 h, then Cps1 mRNA was detected by qPCR.
Cancer Res

Tobacco Smoking Rewires Cell Metabolism by Inducing GAPDH Succinylation to Promote Lung Cancer Progression. [Abstract]

2025 Aug 1;85(15):2838-2857. PMID: 40366632

A-485 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Aug 1;85(15):2838-2857. [Abstract]

A-485 (2 μM; 24 h) suppresses the ascending tendency of GAPDH K251-Su (0.5-6 μM; 24 h) induced by glutamine in NSCLC cells.
Nat Commun

SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma. [Abstract]

2026 Jun 15. PMID: 42297809
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Nat Commun

Cytotoxicity of activator expression in CRISPR-based transcriptional activation systems. [Abstract]

2025 Aug 29;16(1):8071. PMID: 40877321

A-485 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 29;16(1):8071. [Abstract]

A-485 (0.5-8 μM; 24 h) can partially reverse the lysine acetylation induced by wild-type MCP-p300Core.
Nat Commun

β-Hydroxybutyrate promotes cancer metastasis through β-hydroxybutyrylation-dependent stabilization of Snail. [Abstract]

2025 Jul 17;16(1):6592. PMID: 40675949
Nat Commun

Herpesviruses mimic zygotic genome activation to promote viral replication. [Abstract]

2025 Jan 16;16(1):710. PMID: 39814710

A-485 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 16;16(1):710. [Abstract]

A-485 (2.6 and 9.8 nM; 8.5 h) reduces the expression of TRIM43 in HFF1 cells infected with HSV-1 (HSV-1 GFP, MOI 3) (8 h), while the expression of ICP0 and ICP27 remains unchanged.
Nat Commun

Lactate-dependent transcriptional regulation controls mammalian eye morphogenesis. [Abstract]

2023 Jul 14;14(1):4129. PMID: 37452018

A-485 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Jul 14;14(1):4129. [Abstract]

A-485 is a potent Histone acetyltransferase (HAT) inhibitor. Quantification analysis using RT-qPCR shows that Rax and Six3 expression in day 5 cultures are significantly reduced by the addition of A-485 (2 µM) from day 4. Pan-neural marker Sox2 does not show significant change.
Nat Commun

Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid. [Abstract]

2021 Sep 20;12(1):5548. PMID: 34545082
Redox Biol

Oxidative stress-induced ZEB1 acetylation drives a hybrid epithelial-mesenchymal phenotype and promotes lung metastasis in triple-negative breast cancer. [Abstract]

2025 Oct:86:103834. PMID: 40850192
Mol Cell

Chromatin regulation of transcriptional enhancers and cell fate by the Sotos syndrome gene NSD1. [Abstract]

2023 Jul 20;83(14):2398-2416.e12. PMID: 37402365
Nucleic Acids Res

SMAD3 and p300 complex scaffolding by long non-coding RNA LIMD1-AS1 promotes TGF-β-induced breast cancer cell plasticity. [Abstract]

2025 Aug 27;53(16):gkaf841. PMID: 40889156
Theranostics

Astrocyte-derived lactate aggravates brain injury of ischemic stroke in mice by promoting the formation of protein lactylation. [Abstract]

2024 Jul 8;14(11):4297-4317. PMID: 39113798
Theranostics

H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts. [Abstract]

2021 Jan 1;11(3):1473-1492. PMID: 33391546
J Biomed Sci

Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure. [Abstract]

2025 Jul 6;32(1):61. PMID: 40619438
Adv Sci (Weinh)

Identification of A p300-SP1-BRD4 Transcriptional Axis as a Key Driver of AR Hyperactivation in Polycystic Ovarian Syndrome. [Abstract]

2026 Apr;13(23):e18185. PMID: 41684293
Adv Sci (Weinh)

Flipping the Switch: MeCP2-Mediated Lactylation Rewires Microglial Metabolism and Inflammation via the HK2/mTOR Axis in Poststroke Neuroinflammation. [Abstract]

2025 Dec 22:e13400. PMID: 41429663
Adv Sci (Weinh)

Abnormal β-Hydroxybutyrylation Modification of ARG1 Drives Reprogramming of Arginine Metabolism to Promote the Progression of Colorectal Cancer. [Abstract]

2025 Jul 11:e02402. PMID: 40641413
Adv Sci (Weinh)

UGDH Lactylation Aggravates Osteoarthritis by Suppressing Glycosaminoglycan Synthesis and Orchestrating Nucleocytoplasmic Transport to Activate MAPK Signaling. [Abstract]

2025 May;12(20):e2413709. PMID: 40150862

A-485 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 May;12(20):e2413709. [Abstract]

Immunofluorescence staining of Collagen II and Aggrecan in chondrocytes with A485 (0,5,10,20 μM) treatment in the presence of IL-1β. Scale bar, 25 μm.

A-485 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 May;12(20):e2413709. [Abstract]

IHC of Collagen II, Aggrecan, MMP3 and MMP13 of articular cartilage in sham, DMM induced OA mice with A485 (articular injections of 2 µL, 20 mM at 1, 3, 5, and 7 W) or DMSO. (n=8 per group). Scale bars, 50 μm.
Adv Sci (Weinh)

Lactylated Apolipoprotein C-II Induces Immunotherapy Resistance by Promoting Extracellular Lipolysis. [Abstract]

2024 Oct;11(38):e2406333. PMID: 38981044
Adv Sci (Weinh)

YY1 Lactylation Aggravates Autoimmune Uveitis by Enhancing Microglial Functions via Inflammatory Genes. [Abstract]

2024 May;11(19):e2308031. PMID: 38493498
Sci Adv

Deficient chaperone-mediated autophagy facilitates LPS-induced microglial activation via regulation of the p300/NF-κB/NLRP3 pathway. [Abstract]

2023 Oct 6;9(40):eadi8343. PMID: 37801503
Cell Death Differ

Targeting ADAR1 lactylation activates innate immune and overcomes chemoresistance in ovarian cancer. [Abstract]

2026 May 25. PMID: 42185630
Chem Eng J

2021, 130806.
Cell Mol Biol Lett

HK2-driven histone H3K18 lactylation promotes stromal cell senescence and decidualization deficiency in URSA via CUX1-mediated SASP factor transcription. [Abstract]

2026 Mar 9;31(1):31. PMID: 41803676
Cell Death Dis

Oncometabolite fumarate facilitates PD-L1 expression and immune evasion in clear cell renal cell carcinoma. [Abstract]

2025 Jun 3;16(1):432. PMID: 40461489
Cell Death Dis

CBP/p300 HAT maintains the gene network critical for β cell identity and functional maturity. [Abstract]

2021 May 12;12(5):476. PMID: 33980820
Cell Death Dis

Selective inhibition of CBP/p300 HAT by A-485 results in suppression of lipogenesis and hepatic gluconeogenesis. [Abstract]

2020 Sep 11;11(9):745. PMID: 32917859
J Exp Med

PARP7 inhibits type I interferon signaling to prevent autoimmunity and lung disease. [Abstract]

2025 May 5;222(5):e20241184. PMID: 39969510
Acta Pharmacol Sin

Targeting PPARα activation sensitizes glioblastoma cells to temozolomide and reverses acquired resistance by inhibiting H3K18 lactylation. [Abstract]

2025 Jun 11. PMID: 40500345
Cell Death Discov

The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia. [Abstract]

2024 May 1;10(1):206. PMID: 38693103
Acta Pharmacol Sin

P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. [Abstract]

2022 Feb;43(2):457-469. PMID: 33850273
Proc Natl Acad Sci U S A

PARP7 protects the lung epithelial barrier from diverse environmental threats. [Abstract]

2026 Mar 10;123(10):e2525274123. PMID: 41779776
Cell Chem Biol

Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. [Abstract]

2021 Apr 15;28(4):503-514.e12. PMID: 33400925
JHEP Rep

Spatial proteomics and cell-cell cross-talk analysis reveal PD-L1 and IL-6 interaction in human primary sclerosing cholangitis. [Abstract]

2026 May 27:101903. PMID: 42208680
Int J Biol Macromol

KAT8-mediated MDH2 lactylation promotes renal cancer progression by enhancing mitochondrial function and stress resistance. [Abstract]

2025 Aug 5;322(Pt 1):146571. PMID: 40769364
EMBO J

HDAC6-dependent deacetylation of SAE2 enhances SUMO1 conjugation for mitotic integrity. [Abstract]

2025 Aug 20. PMID: 40836035
EMBO J

ATP citrate lyase controls hematopoietic stem cell fate and supports bone marrow regeneration. [Abstract]

2022 Apr 19;41(8):e109463. PMID: 35229328
Mol Med

Epigenetic reprogramming drives endothelial dysfunction via neuropilin-1 in pulmonary hypertension. [Abstract]

2025 Dec 16;31(1):336. PMID: 41402732
Free Radic Biol Med

Bone morphogenetic protein 4 ameliorates corneal neovascularization by inhibiting NLRP3 inflammasome activation through the promotion of CBP-mediated S100A9 acetylation. [Abstract]

2025 Oct:238:430-449. PMID: 40618910
Free Radic Biol Med

MSC-derived exosomes alleviate oxidative stress-induced lysosomal membrane permeabilization damage in degenerated nucleus pulposus cells via promoting m6A demethylation of Nrf2. [Abstract]

2025 Apr 30:S0891-5849(25)00272-2. PMID: 40316061
Cell Rep

2026 Jun 2;45(6).
Cell Rep

Loss of p53 exacerbates autoimmunity by reprogramming propionyl-CoA metabolism and histone modifications in Treg cells. [Abstract]

2026 Mar 15;45(3):117084. PMID: 41838722
Cell Rep

NAD+ sensing by PARP7 regulates the C/EBPβ-dependent transcription program during adipogenesis. [Abstract]

2026 Jan 30;45(2):116929. PMID: 41621069
Cell Rep

TRIM65 as a key regulator of ferroptosis and glycolysis in lactate-driven renal tubular injury and diabetic kidney disease. [Abstract]

2025 Jul 30;44(8):116091. PMID: 40748757
Cell Rep

Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. [Abstract]

2024 Nov 26;43(12):115015. PMID: 39602308
Aging Cell

Histone β-hydroxybutyrylation is critical in reversal of sarcopenia. [Abstract]

2024 Nov;23(11):e14284. PMID: 39076122
Cell Rep

Heterogeneity and transcriptional drivers of triple-negative breast cancer. [Abstract]

2023 Dec 13;42(12):113564. PMID: 38100350
Cell Rep

Interplay between protein acetylation and ubiquitination controls MCL1 protein stability. [Abstract]

2021 Nov 9;37(6):109988. PMID: 34758305
Br J Pharmacol

Dual pharmacological targeting of coactivator-associated arginine methyltransferase 1 (CARM1) and salt inducible kinase (SIK) drives ketogenesis in both hepatocytes and mice. [Abstract]

2026 Apr 29. PMID: 42055601
Cell Syst

Integrated time-series analysis and high-content CRISPR screening delineate the dynamics of macrophage immune regulation. [Abstract]

2025 Aug 20;16(8):101346. PMID: 40782800
J Invest Dermatol

Targeting the Epigenome Reduces Keloid Fibroblast Cell Proliferation, Migration, and Invasion. [Abstract]

2025 Feb;145(2):411-422.e7. PMID: 39009280
J Invest Dermatol

The p300/CBP inhibitor A485 normalizes psoriatic fibroblast gene expression in vitro and reduces psoriasis-like skin inflammation in vivo. [Abstract]

2023 Mar;143(3):431-443.e19. PMID: 36174717
JCI Insight

p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes. [Abstract]

2022 Jan 11;7(1):e141344. PMID: 34813504
Biochem Pharmacol

Acetylation of H3K18 activated by p300 promotes osteogenesis in human adipose-derived mesenchymal stem cells. [Abstract]

2025 Jun:236:116901. PMID: 40164340
J Bone Miner Res

Acetyltransferases CBP/p300 control transcriptional switch of β-catenin and Stat1 promoting osteoblast differentiation. [Abstract]

2023 Dec;38(12):1885-1899. PMID: 37850815
Liver Int

Inhibition of ACSS2 attenuates alcoholic liver steatosis via epigenetically regulating de novo lipogenesis. [Abstract]

2023 Aug;43(8):1729-1740. PMID: 37183518
EMBO Rep

NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis. [Abstract]

2025 Jun;26(12):3106-3137. PMID: 40369363
Stem Cells Transl Med

3D Spheroids Facilitate Differentiation of Human Adipose-Derived Mesenchymal Stem Cells into Hepatocyte-Like Cells via p300-Mediated H3K56 Acetylation. [Abstract]

2024 Feb 14;13(2):151-165. PMID: 37936499
Commun Biol

Deoxynivalenol induces ferroptosis via inhibiting glycolysis-H3K18la-STEAP3 axis to promote ovary damage in piglets. [Abstract]

2025 Nov 20;8(1):1626. PMID: 41266595
Int Immunopharmacol

Lactate represses MHC-I antigen presentation via H4K5 lactylation-PRC2 in small cell lung cancer subtype A. [Abstract]

2026 Feb 1:170:116125. PMID: 41468795
Int J Mol Sci

Generation of Bona Fide Human Induced Trophoblast Stem Cells by Direct Reprogramming of Term Umbilical Cord Cells. [Abstract]

2024 Dec 31;26(1):271. PMID: 39796127
Int J Mol Sci

Hypoxia Increases ATX Expression by Histone Crotonylation in a HIF-2α-Dependent Manner. [Abstract]

2023 Apr 11;24(8):7031. PMID: 37108194
Int Immunopharmacol

p300/CBP inhibitor A-485 inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. [Abstract]

2021 May:94:107458. PMID: 33626422
Phenomics

2026 Jun 10.
Biol Direct

PNSC928, a plant-derived compound, specifically disrupts CtBP2-p300 interaction and reduces inflammation in mice with acute respiratory distress syndrome. [Abstract]

2024 Jun 21;19(1):48. PMID: 38902802
Biol Res

Decoding a novel non-enzymatic protein acetylation mechanism in sperm that is essential for fertilizing potential. [Abstract]

2025 May 29;58(1):30. PMID: 40442844
Toxicology

H3K18 lactylation-mediated SIX1 upregulation contributes to silica-induced epithelial-mesenchymal transition in airway epithelial cells. [Abstract]

2025 Jun:514:154109. PMID: 40049282
PLoS Pathog

HBZ upregulates myoferlin expression to facilitate HTLV-1 infection. [Abstract]

2023 Feb 24;19(2):e1011202. PMID: 36827461
PLoS Pathog

Bacterial infection promotes tumorigenesis of colorectal cancer via regulating CDC42 acetylation. [Abstract]

2023 Feb 22;19(2):e1011189. PMID: 36812247
Cancers (Basel)

CIC-DUX4 Chromatin Profiling Reveals New Epigenetic Dependencies and Actionable Therapeutic Targets in CIC-Rearranged Sarcomas. [Abstract]

2024 Jan 21;16(2):457. PMID: 38275898
Cancers (Basel)

LncRNA LINC00518 Acts as an Oncogene in Uveal Melanoma by Regulating an RNA-Based Network. [Abstract]

2020 Dec 21;12(12):3867. PMID: 33371395
Cell Signal

Cadmium contributes to cardiac metabolic disruption by activating endothelial HIF1A-GLUT1 axis. [Abstract]

2024 Jul:119:111170. PMID: 38604344
Brain Res Bull

Inhibiting H3K18 lactylation in microglia aggravates white matter injury after intracerebral hemorrhage in mice. [Abstract]

2026 Feb:235:111744. PMID: 41616944
iScience

Global isonicotinylome analysis identified SMAD3 isonicotinylation promotes liver cancer cell epithelial-mesenchymal transition and invasion. [Abstract]

2024 Aug 21;27(9):110775. PMID: 39286495
ACS Chem Neurosci

Domain-Independent Inhibition of CBP/p300 Attenuates α-Synuclein Aggregation. [Abstract]

2021 Jul 7;12(13):2273-2279. PMID: 34110772
BMC Cancer

Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition. [Abstract]

2025 May 28;25(1):955. PMID: 40437414
Pathogens

Upregulation of Neuropilin-1 Inhibits HTLV-1 Infection. [Abstract]

2023 Jun 15;12(6):831. PMID: 37375521
Cancer Med

Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma. [Abstract]

2026 Jun;15(6):e71985. PMID: 42231094
Exp Cell Res

MiR-34a-5p promotes hepatic gluconeogenesis by suppressing SIRT1 expression. [Abstract]

2022 Nov 1;420(1):113336. PMID: 36058294
Tissue Cell

H3K27 acetylation activated-CCS regulates autophagy and apoptosis of lung cancer by alleviating oxidative stress. [Abstract]

2023 Feb:80:101964. PMID: 36402120
Mol Biol Cell

Interplay of condensation and chromatin binding underlies BRD4 targeting. [Abstract]

2024 Jun 1;35(6):ar88. PMID: 38656803
Insects

BmCBP Catalyzes the Acetylation of BmApoLp-II Protein and Regulates Its Stability in Silkworm, Bombyx mori. [Abstract]

2023 Mar 23;14(4):309. PMID: 37103124
Biochem Biophys Res Commun

Apigenin suppresses epithelial-mesenchymal transition in high glucose-induced retinal pigment epithelial cell by inhibiting CBP/p300-mediated histone acetylation. [Abstract]

2024 Jul 12:717:150061. PMID: 38718570
Biochem Biophys Res Commun

Upregulation of α enolase (ENO1) crotonylation in colorectal cancer and its promoting effect on cancer cell metastasis. [Abstract]

2021 Sep 16;578:77-83. PMID: 34547627
Biomed Chromatogr

Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantification of the acetyl-coenzyme A competitive p300/CBP catalytic inhibitor A-485 in biological samples. [Abstract]

2024 Apr;38(4):e5819. PMID: 38148286
University of North Carolina at Chapel Hill

2026.
bioRxiv

Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States. [Abstract]

2026 May 26:2026.05.22.726988. PMID: 42244620
bioRxiv

ATGL-catalyzed lipid catabolism promotes DNA repair. [Abstract]

2026 Apr 4:2026.04.03.716381. PMID: 41959418
bioRxiv

Divergent condensates tune transcriptional responses during stress. [Abstract]

2026 Feb 13:2026.02.12.705659. PMID: 41727155
bioRxiv

2026 Jan 14.
bioRxiv

Tau seeding in neurons enabled by transient endolysosomal perforations are confined within endolysosomes. [Abstract]

2025 Nov 3:2025.11.02.686178. PMID: 41278722
bioRxiv

Short chain fatty acids regulate the chromatin landscape and distinct gene expression changes in human colorectal cancer cells. [Abstract]

2025 May 13:2025.05.07.652677. PMID: 40463142
bioRxiv

Bypass of Blocking Lesions by RNAPII Impairs the Transcriptional DNA Damage Response. [Abstract]

2025 Apr 28:2025.04.28.651040. PMID: 40492193
Environ Toxicol

H3K27 Acetylation-Activated GLDC Accelerated the Advancement of Oral Squamous Cell Carcinoma by Suppressing the p53 Signaling Pathway. [Abstract]

2025 Jan;40(1):140-151. PMID: 39415627
bioRxiv

The CoREST-complex regulates MYC stability and promotes post-transcriptional mRNA splicing in melanoma. [Abstract]

2024 Dec 23:2024.12.23.630174. PMID: 39764010
bioRxiv

2024 July 27.
Chemrxiv

2024 Mar 26.
bioRxiv

2024 Feb 7.
bioRxiv

2024 Feb 16.
Biomed Pharmacother

XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma. [Abstract]

2023 Apr:160:114402. PMID: 36791564

A-485 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Apr:160:114402. [Abstract]

A485 (1, 3 µM; 4 h) reduces endogenous acetylation of NPM1 in HA-NPM1-transfected Huh7/SR NPM1 KD cells.
Research Square Preprint

2023 Apr 11.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (186.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8640 mL

9.3200 mL

18.6400 mL

5 mM

0.3728 mL

1.8640 mL

3.7280 mL

10 mM

0.1864 mL

0.9320 mL

1.8640 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: 11 mg/mL (20.50 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay^[1]

Cell lines are plated in 96 well or 384 well plates and allowed to adhere for 24 h. The cells are then treated with A-485 for 3, 4, or 5 days. Experiments are run in triplicate and the fraction of viable cells is determined using the Cell Viability Assay according to the manufacturer’s recommendations. For Thymidine incorporation assays, cells are treated with A-485 for 1, 2, 3, or 4 days. Twenty four hours prior to the time point, tritiated thymidine is added and cells are incubated for an additional 24 h. Genomic DNA is then isolated on filter plates^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

The LuCap-77 CR prostate PDX model is used in this study. Donor tumors are dissociated and injected as a brie (1:2) into the right flank of 16 week old male C.B.-17 SCID mice on day 0 in a volume of 0.2 mL. Tumors are size matched on day 26 post-inoculation with a mean tumor volume of 211±3 (SEM) mm³ with dosing beginning on day 28. Mice are randomized into treatment groups using Studylog software based on tumor volume. LuCap-77 CR xenograft tumors are established in SCID mice and animals are dosed with A-485 as for 7 days. Three hours post the final dose, tumors are harvested and snap frozen on dry ice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (278 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Lasko LM, et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature. 2017 Oct 5;550(7674):128-132. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8640 mL	9.3200 mL	18.6400 mL	46.6001 mL
	5 mM	0.3728 mL	1.8640 mL	3.7280 mL	9.3200 mL
	10 mM	0.1864 mL	0.9320 mL	1.8640 mL	4.6600 mL
	15 mM	0.1243 mL	0.6213 mL	1.2427 mL	3.1067 mL
	20 mM	0.0932 mL	0.4660 mL	0.9320 mL	2.3300 mL
	25 mM	0.0746 mL	0.3728 mL	0.7456 mL	1.8640 mL
	30 mM	0.0621 mL	0.3107 mL	0.6213 mL	1.5533 mL
	40 mM	0.0466 mL	0.2330 mL	0.4660 mL	1.1650 mL
	50 mM	0.0373 mL	0.1864 mL	0.3728 mL	0.9320 mL
	60 mM	0.0311 mL	0.1553 mL	0.3107 mL	0.7767 mL
	80 mM	0.0233 mL	0.1165 mL	0.2330 mL	0.5825 mL
	100 mM	0.0186 mL	0.0932 mL	0.1864 mL	0.4660 mL

Keywords

A-485

110 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

A-485

Reprogramming Compound Library

Endocrinology Compound Library

Chemical Probe Library

Anti-Blood Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Epigenetics Compound Library Mini

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Publications Citing Use of MedChemExpress (MCE) A-485

Voir tous les produits spécifiques à Isoform Epigenetic Reader Domain

Voir tous les produits spécifiques à Isoform Histone Acetyltransferase

Activité biologique

Chemical Information

Publications (110)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

A-485

Reprogramming Compound Library

Endocrinology Compound Library

Chemical Probe Library

Anti-Blood Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Epigenetics Compound Library Mini

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Publications Citing Use of MedChemExpress (MCE) A-485

Voir tous les produits spécifiques à Isoform Epigenetic Reader Domain

Voir tous les produits spécifiques à Isoform Histone Acetyltransferase

Activité biologique

Chemical Information

Publications (110)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

A-485 Related Classifications

HY-107455 Related Classifications